Cellular Biomedicine Group Hk Limited

Cellular Biomedicine Group, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Semiconductor Manufacturing International Corp.

Casco Signal Ltd.

Synacast Computer System (Shanghai)

Abelzeta Inc.

Xin Yao

Yanfeng Li

Yutian Wei

Yihong Yao

Jiaqi Huang

Shigui Zhu

Lin Zhu

Wei Zhu

Li Zhang

Qingxia Wang

Jiaping He

Zhiyuan Li

Anyun Ma

Qiang Wu

Steven A Rosenberg

Chang Liu

Paul F Robbins

Yiming Gu

Jing'An Hao

Qiang Shu

Xiaoteng Lv

Tianhui Li

Fang Liu

Lei Feng

Fei Lu

Hongjun Jiang

Xiaoguang Li

Wenhao Shi

Wenyu Wang

Cece Zhou

The invention relates to a method for guaranteeing the reliability of real-time scrambling and message transmission by a train control center system. The method comprises the following steps: S1, starting the system for offline message loading and reading; S2, obtaining message data to be scrambled; S3, sending the message to be scrambled to a scrambling operation board for scrambling; S4, performing inverse decoding processing on an operation board; S5, performing comparison after decoding; and S6, outputting effective message data. Compared with the prior art, the invention has the advantages of being capable of guaranteeing the safety and reliability of message data.

Method for guaranteeing reliability of real-time scrambling and message transmission by train control center system

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.

Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof

Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.

BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof

The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.

T cell receptors recognizing MHC class II-restricted MAGE-A3

An exposure method and an exposure device are provided. An exemplary exposure device includes a stage, a first clamp holder, a second clamp holder, an optical projection unit, a first alignment detection unit, and/or a second alignment detection unit. The stage includes a first region and a second region. The first clamp holder is located in the first region and adapted for holding a first substrate, and the second clamp holder is located in the second region and adapted for holding a second substrate. The optical projection unit is located above the stage and adapted for exposure of the first substrate or the second substrate. The first alignment detection unit is adapted for detecting alignment marks of the first substrate. The second alignment detection unit is adapted for detecting alignment marks of the second substrate. The exposure device can accurately position the stage and improve production yield.

Exposure device and exposure method

The present invention has provided a method for live broadcasting in distributed network and means for the same. Wherein the method mainly comprises steps of: tracker servers receive the status report information from the program source connected to the tracker server; generates the status information of the program source based on said status report information; sends status information of the program source to the information synchronization means.

Method for live broadcasting in a distributed network and apparatus for the same

The present disclosure provides a lithography machine and a scanning and exposing method thereof. According to the scanning and exposing method, the scanning and exposing process for a whole wafer includes two alternately circulated motions: a scanning and exposing motion and a stepping motion; and the scanning and exposing motion is a sinusoidal motion rather than a rapid-acceleration uniform-speed rapid-deceleration scanning and exposing motion in the conventional techniques. During the scanning of a single exposure shot, it may begin to scan the exposure shot once a wafer stage and a reticle stage begin to accelerate from zero speed. And the scanning and exposing may not end until the speeds of the wafer stage and the reticle decrease to zero. Therefore, the effective time of the scanning and exposing in the scanning and exposing motion is greatly increased and the production efficiency of the wafer is improved.

Lithography machine and scanning and exposing method thereof

Growing community of inventors

Hong Kong, China

Xin Yao